Zacks Small Cap Analysis – XFOR: XOLREMDI Permitted by FDA…
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Enterprise Replace XOLREMDI Permitted by the FDA On April 29, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced that the U.S. Meals and Drug Administration (FDA) has authorised XOLREMDI (mavorixafor) to be used in sufferers 12 years of age and older with WHIM syndrome (warts, … Read more